SLC1A5 and neoplasm: V-9302 can block the ASCT2-mediated transport that inhibits glutamine uptake and has been considered as a targeted therapy in tumor cells, since it attenuates proliferation, increasing oxidative stress and cell death, and shows better potency and selectivity than GPNA [69].